HC Wainwright Comments on Arcturus Therapeutics Holdings Inc.’s Q4 2025 Earnings (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities research analysts at HC Wainwright issued their Q4 2025 earnings estimates for Arcturus Therapeutics in a note issued to investors on Wednesday, August 7th. HC Wainwright analyst E. Arce anticipates that the biotechnology company will post earnings of $0.95 per share for the quarter. HC Wainwright has a “Buy” rating and a $63.00 price target on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($4.74) per share.

ARCT has been the subject of several other reports. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Tuesday. Finally, Canaccord Genuity Group cut their price objective on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a research report on Friday, May 10th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Arcturus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $68.20.

Arcturus Therapeutics Stock Down 3.8 %

ARCT traded down $0.71 on Thursday, hitting $18.08. 466,267 shares of the company traded hands, compared to its average volume of 515,070. The company has a 50 day moving average of $25.76 and a 200-day moving average of $30.64. Arcturus Therapeutics has a 12-month low of $17.52 and a 12-month high of $45.00. The stock has a market capitalization of $486.93 million, a PE ratio of -4.62 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The firm had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. During the same quarter in the prior year, the business earned ($1.98) EPS.

Insider Activity at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 26,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total value of $1,040,260.00. Following the sale, the chief operating officer now directly owns 447,448 shares in the company, valued at $17,902,394.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ARCT. Quest Partners LLC grew its position in shares of Arcturus Therapeutics by 3,283.5% in the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 3,579 shares during the period. ARK Investment Management LLC grew its holdings in Arcturus Therapeutics by 16.3% in the 2nd quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after buying an additional 275,315 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Arcturus Therapeutics by 3.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 119,181 shares of the biotechnology company’s stock valued at $2,902,000 after acquiring an additional 3,578 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Arcturus Therapeutics by 8.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 34,660 shares of the biotechnology company’s stock worth $844,000 after acquiring an additional 2,730 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Arcturus Therapeutics by 22.4% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after acquiring an additional 286,546 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.